[
  {
    "ts": null,
    "headline": "Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.",
    "summary": "Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.",
    "url": "https://finnhub.io/api/news?id=419b097963dfa4a43b4a84cafebb9ef46b0d55a5dafa5472eb05116de58124f3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758905460,
      "headline": "Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.",
      "id": 136921039,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.",
      "url": "https://finnhub.io/api/news?id=419b097963dfa4a43b4a84cafebb9ef46b0d55a5dafa5472eb05116de58124f3"
    }
  },
  {
    "ts": null,
    "headline": "Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?",
    "summary": "ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.",
    "url": "https://finnhub.io/api/news?id=f94823b0b710280a05310f850e35629c0191f2798fbdc1ec587b9d079aefbf90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758901500,
      "headline": "Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?",
      "id": 136896933,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.",
      "url": "https://finnhub.io/api/news?id=f94823b0b710280a05310f850e35629c0191f2798fbdc1ec587b9d079aefbf90"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease",
    "summary": "AbbVie (NYSE: ABBV) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tavapadon, a novel selective dopamine D1/D5 receptor partial agonist that was studied as a once daily oral treatment for Parkinson's disease.",
    "url": "https://finnhub.io/api/news?id=dbb51fc702733348fe185bbb8eef6ba7999db302be291c89c89f8da2f7443198",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758890700,
      "headline": "AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease",
      "id": 136892686,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tavapadon, a novel selective dopamine D1/D5 receptor partial agonist that was studied as a once daily oral treatment for Parkinson's disease.",
      "url": "https://finnhub.io/api/news?id=dbb51fc702733348fe185bbb8eef6ba7999db302be291c89c89f8da2f7443198"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Files for FDA Approval of Oral Parkinson's Treatment Tavapadon",
    "summary": "AbbVie Files for FDA Approval of Oral Parkinson's Treatment Tavapadon",
    "url": "https://finnhub.io/api/news?id=5092905ab512941379035903a7c385231bfec02e60ac0c5fa6eec72beb9ef054",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758877860,
      "headline": "AbbVie Files for FDA Approval of Oral Parkinson's Treatment Tavapadon",
      "id": 136921408,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Files for FDA Approval of Oral Parkinson's Treatment Tavapadon",
      "url": "https://finnhub.io/api/news?id=5092905ab512941379035903a7c385231bfec02e60ac0c5fa6eec72beb9ef054"
    }
  }
]